Cue Biopharma (NASDAQ:CUE) Receives New Coverage from Analysts at HC Wainwright

Investment analysts at HC Wainwright initiated coverage on shares of Cue Biopharma (NASDAQ:CUE) in a report issued on Thursday, PriceTargets.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 101.01% from the company’s current price.

Other analysts have also recently issued research reports about the company. JMP Securities restated a “buy” rating and set a $29.00 price objective on shares of Cue Biopharma in a research note on Wednesday, November 17th. Craig Hallum started coverage on Cue Biopharma in a research note on Monday, January 3rd. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Zacks Investment Research lowered Cue Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, November 17th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $27.00.

NASDAQ:CUE opened at $9.95 on Thursday. Cue Biopharma has a one year low of $9.32 and a one year high of $18.42. The business’s 50-day simple moving average is $12.45 and its 200 day simple moving average is $12.15. The stock has a market cap of $316.02 million, a price-to-earnings ratio of -6.55 and a beta of 1.45.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Tuesday, November 9th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.02). Cue Biopharma had a negative return on equity of 65.79% and a negative net margin of 654.55%. The business had revenue of $2.40 million during the quarter, compared to analyst estimates of $1.60 million. As a group, equities research analysts expect that Cue Biopharma will post -1.43 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Cue Biopharma by 0.5% in the 3rd quarter. BlackRock Inc. now owns 2,160,458 shares of the company’s stock worth $31,476,000 after buying an additional 11,660 shares in the last quarter. State Street Corp grew its holdings in Cue Biopharma by 7.3% in the 2nd quarter. State Street Corp now owns 1,470,075 shares of the company’s stock worth $17,126,000 after buying an additional 99,470 shares in the last quarter. 683 Capital Management LLC grew its holdings in Cue Biopharma by 5.6% in the 3rd quarter. 683 Capital Management LLC now owns 743,772 shares of the company’s stock worth $10,837,000 after buying an additional 39,552 shares in the last quarter. Woodline Partners LP grew its holdings in Cue Biopharma by 229.0% in the 2nd quarter. Woodline Partners LP now owns 667,224 shares of the company’s stock worth $7,773,000 after buying an additional 464,418 shares in the last quarter. Finally, Prosight Management LP grew its holdings in Cue Biopharma by 3.9% in the 3rd quarter. Prosight Management LP now owns 655,185 shares of the company’s stock worth $9,546,000 after buying an additional 24,821 shares in the last quarter. 53.19% of the stock is owned by institutional investors and hedge funds.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease.

Read More: What are the components of an earnings report?

Analyst Recommendations for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.